Observation of domestic imatinib on advanced gastrointestinal stromal tumors
CHEN Xin
ZHANG Bo
LI Jian
ZHANG Jun
SUN Xiaofeng
QU Hongyan
ZHANG Xinhua.
Abstract：Objective To investigate the efficacy and safety of domestic imatinib in the treatment of advanced gastrointestinal stromal tumors (GIST). Methods From May 2005 to June 2018, 97 patients with advanced GIST confirmed by pathology were col?lected retrospectively.All patients were treated with oral domestic imatinib.The initial does was 400 mg／d for 89 patients, and 300 mg／d for 8 patients. The efficacy and safety were analyzed. Results The median time of imatinib duration was 11 months, ranging from 1 to 53 months. Among the 97 patients, there were 13 cases of CR, 56 cases of PR, 18 cases of SD and 10 cases of PD, respectively. The effective rate was 71. 1% and the disease control rate was 89. 7%. The 1?year and 3?year progression?free survival rates were 88. 5% and 68. 1%. The common adverse effects were facial and lower limbs edema, gastrointestinal symptoms and fatigue, mainly in grade 1 to 2. Conclusion Domestic imatinib is effective and safe for patients with post?operative recurrence, metastasis and primary unresectable GIST, and its side effects are often mild.
Keywords：Gastrointestinal stromal tumors(GIST)ImatinibEfficacySafety
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 632-635 )